Reviewer’s report

Title: Outcomes following administration of tranexamic acid in combat-related intracranial hemorrhage: a cohort study

Version: 0 Date: 28 Jan 2020

Reviewer: joel tochie

Reviewer's report:

Congratulations to the authors for choosing to work on a topic of tremendous importance in emergency medicine. The manuscript is original and quite interesting. Kindly find some few review comments below

Title: there is not specific and it is redundant. Also the word combat is not specific to this study which includes participants of the army force. Combat can also refer to boxers, does doing catch or marchal acts. Suggested title: Outcomes of tranexamic acid administration in military trauma patients with intracranial hemorrhage: a cohort study

Methods: page 2, line 25: change combat casualties to army force survivors

Main text
Page 4, line 15 to 31: please provide references to support your sentences
Page 4; line 10: change receive to received
Page 5, line 7: change combat to army
Page 5, line 54: you stated guidelines recommend that TXA is effective in TBI if started within 3 hours. Is it not important mentioning this time frame as your inclusion criteria?
Page 6, line 12: please specify the name of the local Institutional review board and the authorization number issued by this board
Page 6, line 46: Please specify cerebral CT-scan and not barley CT-scan. CT-scan was performed at what interval to follow the progression of ICH. Is it possible to know the number of barrettes of the CT-scan machine, was the CT-scan performed by residents or one or several radiologists. If by radiologists what is their average number of professional experience since qualification. All these data aims at reducing bias

Methods:
* mention ISS as a study variable and spell it out in full before its utilisation in the result section
* please define TBI, ICH, casualties, massive transfusion seen in your methods

Result:
* page 8, line 49 to 59: what was the blood lost, pre-TXA hemoglobin, amount of blood unit transfused, post-TXA hemoglobin between those who received TXA and those who did not?
* Apart from the GCS, what was the functional outcome after TXA administration?
* Did your patients with ICH present with signs of intracranial hypertension? if yes how many, what was the mean intracranial hypertension, apart from decompressive craniotomy, was mannitol used?

Page 9, line 41: please provide a table of the multivariate analysis done for better transparency of results

Discussion
Page 11, line 35: cite the reference studies you refer too please
Page 11, line 23: change more research to more prospective large-sample size randomized controlled trials
Page 13, line 17: change TBI take to TBI to take
Page 13, line 20: change capability to facility

References
Please your reference should not have the month and day of publication in order to be in conformity with Vancouver referencing

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Unable to assess

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I recommend additional statistical review

Quality of written English
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?
4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal